Savill Corrine
Known title: Acting Chief Business OfficerCIK: 0001837524
Associated companies
Transaction History
| CGEM | ▲ Buy | Grant | 37,500 | $0 | 2/19/2025 | View on chart |
| CGEM | ▲ Buy | Grant | 37,500 | $0 | 2/22/2024 | View on chart |
| CGEM | ▲ Buy | Option Exercise | 40,000 | $172K | 2/1/2024 | View on chart |
| CGEM | ▼ Sell | Open Market | 40,000 | $647K | 2/1/2024 | View on chart |
| CGEM | ▼ Sell | Open Market | 40,000 | $564K | 1/29/2024 | View on chart |
| CGEM | ▲ Buy | Option Exercise | 40,000 | $172K | 1/29/2024 | View on chart |
| CGEM | ▼ Sell | Open Market | 21,316 | $266K | 1/23/2024 | View on chart |
| CGEM | ▲ Buy | Option Exercise | 21,316 | $92K | 1/23/2024 | View on chart |
| CGEM | ▲ Buy | Option Exercise | 14,559 | $63K | 1/22/2024 | View on chart |
| CGEM | ▼ Sell | Open Market | 14,559 | $177K | 1/22/2024 | View on chart |
| CGEM | ▼ Sell | Open Market | 4,125 | $50K | 1/22/2024 | View on chart |
| CGEM | ▲ Buy | Grant | 20,500 | $0 | 2/17/2023 | View on chart |
| CGEM | ▼ Sell | Open Market | 14,958 | $228K | 7/19/2022 | View on chart |
| CGEM | ▼ Sell | Open Market | 5,042 | $76K | 7/18/2022 | View on chart |
| CGEM | ▼ Sell | Open Market | 39,800 | $531K | 7/11/2022 | View on chart |
| CGEM | ▼ Sell | Open Market | 200 | $3K | 7/11/2022 | View on chart |
| CGEM | ▲ Buy | Grant | 16,500 | $0 | 2/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cullinan delays arthritis data update to December
Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.
Cullinan delays arthritis data update to December. Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.